Lv7
4880 积分 2023-03-05 加入
A review investigating delays in Crohn's disease diagnosis
24天前
已关闭
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
2个月前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
2个月前
已完结
Early Biological Therapy Within 12 Months of Diagnosis Leads to Higher Transmural Healing Rates in Crohn’s Disease
2个月前
已完结
Comparative Effectiveness of Infliximab vs Ustekinumab for Endoscopic and Transmural Remission in Biologic Naïve Crohn’s Disease
2个月前
已完结
Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing
2个月前
已完结
Transmural healing as a therapeutic goal in Crohn's disease: a systematic review
2个月前
已完结
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
2个月前
已完结
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
2个月前
已完结
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis
3个月前
已完结
皖公网安备34019202002308
